June 27, 2013
Nuvilex Gains From Positive Cannabidiol Study
Innovation, along with the development of solutions to desperately desired unmet needs are the key drivers of virtually all scientific work. These characteristics are perhaps magnified in the field of medicine, especially in the case of terminal or chronic diseases. Moreover, as innovation in medicine succeeds during research and development, it fosters the potential of success throughout the industry, thereby benefitting both scientists and researchers from many firms but also patients.
For example, Medical Marijuana Sciences, Inc., a subsidiary of Nuvilex, Inc. (OTCQB – NVLX - $0.105 – Spec Buy), is in the formative stages of studying the effect of cannabidiol (CBD)-based cancer treatments which may be combined with its highly efficacious live-cell encapsulation-based therapies used for oncology therapy. A number of companies have engaged in some form of lab testing or even animal testing of medical marijuana-based or CBD-based treatment for specific forms of cancer. With each succeeding study, the industry draws closer to the commencement of large-scale, meaningful oncology clinical trials and Nuvilex, along with cancer patients, arguably remain the greatest beneficiaries.
Each trial or study success, such as the recently announced California Pacific Medical Center in San Francisco CBD-study, serves as an affirmation of the premise that CBD can aid in oncology treatment, and indirectly aids Nuvilex’s efforts in the space as the Company can leverage findings for use in protocol development for its own studies.
Leaders of the aforementioned CBD tests found that cannabidiol, or CBD, a relatively non-toxic, non-psychoactive chemical compound found in the cannabis plant, could stop the metastasis or spread, of many kinds of aggressive cancer. Lab tests demonstrated that by using CBD to treat cancers with high levels of ID-1, a gene that causes cancer to spread, the CBD could essentially 'turn off' the ID-1 gene. As a result, the cancer cells stopped spreading and returned to a more “normal” state.
Considering that Nuvilex likely has much greater experience in successfully conducting oncology clinical trials than any other player in the space, it is anecdotal evidence such as the San Francisco study that may serve to shorten Nuvilex’s own overall research and development times. Thus, Nuvilex’s combination CBD-based cancer studies with live-cell encapsulation-based therapies might result in bringing a highly effective product potentially worth billions to market in a shorter period of time than its competitors.
You Might Also Like
Senior Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.